ReviewCancers2022
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
Open access · goldAbstract readReview
In one paragraph
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer.European journal of clinical pharmacology · 2024Pooled it
- CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials.Frontiers in oncology · 2022Pooled it
- Trial
- Continuous glucose monitoring-guided management of capivasertib-associated hyperglycemia: A case series of three patients.Journal of diabetes investigation · 2026Article
- [Genetic, endocrine, drug-induced and pancreatogenic forms of diabetes and exocrine pancreatic insufficiency (Update 2026)].Wiener klinische Wochenschrift · 2026Review
- Consensus on the Management of Inavolisib Side Effects. A Survey on Defined Side Effects, the Assumed Pathomechanism, Preventative and/or Therapeutic Measures Including the Integration of Additional Health Care Professionals - a Consensus Paper.Geburtshilfe und Frauenheilkunde · 2026Article
- Article
- Article
- Metabolic reprogramming in diabetes and cancer: the role of PI3K/AKT/mTOR and beyond.American journal of cancer research · 2026Review
- Inavolisib-induced fulminant-like diabetes and hyperosmolar hyperglycemic state: a case report.Frontiers in endocrinology · 2026Article
- Selective phosphoinositide 3-kinase inhibitors and implication in diabetic retinopathy as pharmacological tools.Frontiers in pharmacology · 2026Review
- Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion.NPJ breast cancer · 2025Review
- Understanding the conformational dynamics of PI3Kα due to helical domain mutations: insights from Markov state model analysis.Molecular diversity · 2025Article
- NICTH with secondary acromegaloid changes and severe hypoglycemia due to potentially insulin-like growth factor-2 mediated effects.Journal of diabetes and metabolic disorders · 2025Article
- Dynamic changes of blood glucose level during capivasertib treatment in metastatic breast cancer: a case report.Diabetology international · 2025Article
- Review
- Dynamics of hyperglycemia of patients treated with alpelisib: exploratory interim analysis of ITACA trial.The oncologist · 2025Article
- Metformin enhances alpelisib sensitivity in HER2+ breast cancer by suppressing cancer stemness and oncogenic signaling.Frontiers in oncology · 2025Article
- Synthesis of thiazole-integrated pyrrolotriazinones: evaluations of cytotoxicity and effects on PI3K levels in cancer cells.Turkish journal of chemistry · 2025Article
- Hyperglycemia secondary to phosphatidylinositol-3 kinase (PI3K) inhibition.Endocrinology, diabetes & metabolism case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 12 countries.
Tsvetalina TankovaDepartment of Endocrinology, Medical University of Sofia, 2, Zdrave Str., 1431 Sofia, Bulgaria.ORCID 0000-0002-7572-1131
Elżbieta SenkusDepartment of Oncology & Radiotherapy, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland.ORCID 0000-0001-6855-397X
Maria BeloyartsevaInstitution N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, 23 Kashirskoye Avenue, 115478 Moscow, Russia.
Simona BorštnarDivision of Medical Oncology, Institute of Oncology Ljubljana, Zaloska 2, 1000 Ljubljana, Slovenia.
Doina CatrinoiuDepartment of Diabetology, Clinical Emergency Hospital of Constanta, Romania, Tomis Bvd. No. 145, 900591 Constanta, Romania.
Mona FrolovaInstitution N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, 23 Kashirskoye Avenue, 115478 Moscow, Russia.
Alinta HegmaneOut-Patient Department of Medical Oncology, Riga East University Hospital, Oncology Center of Latvia, 4, Hipokrata Str., LV1079 Riga, Latvia.
Andrej JanežDepartment of Endocrinology, Diabetes and Metabolic Disease, University Medical Center, Zaloska 7, 1000 Ljubljana, Slovenia.
Mladen KrnićDepartment of Endocrinology, Clinical Hospital Center Split, School of Medicine, University of Split, Šoltanska 1, 21000 Split, Croatia.
Zoltan LengyelSzent János Hospital, Diós árok 1-3, 1125 Budapest, Hungary.
Yiola MarcouMedical Oncology Department, The Bank of Cyprus Oncology Centre, 32 Acropoleos Avenue, Strovolos, Nicosia 2006, Cyprus.
Laura MaziluDepartment of Diabetology, Clinical Emergency Hospital of Constanta, Romania, Tomis Bvd. No. 145, 900591 Constanta, Romania.ORCID 0000-0001-6195-4500
Bela Mrinakova1st Department of Oncology, Comenius University, Faculty of Medicine, Bratislava, Heydukova 10, 812 50 Bratislava, Slovakia.ORCID 0000-0001-9795-0640
Ruth PercikDivision of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel.
Katarina PetrakovaMasaryk Memorial Cancer Institute, Žlutý kopec 543/7, Brno-Střed-Staré, 602 00 Brno, Czech Republic.
Gábor RubovszkyNational Institute of Oncology, Rath Gy. Str. 7-9, 1122 Budapest, Hungary.
Margarita TokarThe Legacy Heritage Oncology Center and Dr. Larry Norton Institute, SorokaMedical Center, Yitzhack I. Rager Blvd 151, Be'er Sheva, Israel.
Eduard VrdoljakDepartment of Oncology, Clinical Hospital Center Split, School of Medicine, University of Split, Spinčićeva 1, 21000 Split, Croatia.
Ministry of Health of the Russian Federation · RUOvidius University · ROUniversity of Split · HRBank of Cyprus Oncology Center · CYComenius University Bratislava · SKGdańsk Medical University · PLInstitute of Oncology Ljubljana · SILjubljana University Medical Centre · SIMasaryk Memorial Cancer Institute · CZMedical University of Sofia · BGNational Institute of Oncology · HURiga East University Hospital · LVSoroka Medical Center · ILSzent János Kórház · HUTel Aviv University · IL
Funding
Novartis (Switzerland) not applicable
Abstract
Alpelisib is an α-selective phosphatidylinositol 3-kinase inhibitor used for treating hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2-),
Indexed as
adverse effectalpelisibhyperglycemiaPIK3CA-mutated metastatic breast cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.